Is complete really complete? Prognostic divergence of pathological…
OBJECTIVE: To review whether pathological complete response (pCR) in esophageal adenocarcinoma (AC) may be regime-dependent and to outline its implications for surveillance, adjuvant therapy and trial design. Pathological complete response remains a favorable prognostic indicator relative to residual disease after neoadjuvant therapy, but postoperative ctDNA may further stratify recurrence risk within the pCR population.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
A machine learning-derived sarcopenia index is associated with…
Body composition analysis (BCA) provides an objective assessment of metabolic states, but its prognostic value in diffuse large B-cell lymphoma (DLBCL) remains unclear. Taken together, our results establish baseline sarcopenia and treatment-emergent muscle loss as orthogonal risk factors for adverse outcomes in DLBCL, supporting the evaluation of BCA for risk stratification in personalized lymphoma therapy.
Novel or significantly improved treatmentEplontersen for Transthyretin Amyloid Cardiomyopathy.
BACKGROUND: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease caused by deposition of misfolded transthyretin (TTR). RESULTS: A total of 1432 patients underwent randomization and received at least one dose of the assigned intervention (715 patients in the eplontersen group and 717 in the placebo group).
Novel or significantly improved treatmentEfficacy of Vibegron in Overactive Bladder
OBJECTIVES: To synthesize published placebo-controlled trials of vibegron monotherapy for overactive bladder (OAB) and quantify posterior probabilities of benefit and decision-threshold exceedance. CONCLUSIONS: Bayesian cross-trial synthesis demonstrates a high probability that vibegron improves key OAB voiding-diary outcomes at Week 12.
Novel or significantly improved treatmentAlkaline Phosphatase and Prostate-specific Antigen Response in…
DESIGN, SETTING, AND PARTICIPANTS: Exploratory post hoc analysis of the international, randomised, open-label phase 3 PEACE-3 trial including 446 patients with asymptomatic or mildly symptomatic mCRPC and bone metastases. RESULTS AND LIMITATIONS: At 6 months, confirmed ALP-30 response was 56.5% with the combination versus 50.8% with enzalutamide alone.